Lonza Opens New ADC Payload Manufacturing Facility

10th November 2020

Lonza Opens New ADC Payload Manufacturing Facility

Lonza has inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at its Visp, Switzerland site.
This first manufacturing suite, dedicated to the manufacturing platform for ADC drug linkers, can handle a variety of highly potent compounds with occupational exposure levels down to 1 ng/m3.
The new highly-potent API (HPAPI) suite has been in operation since March of this year. Lonza said that a second suite will become available to customers early in 2021.

According to Lonza, the new suites will extend the options for companies developing APIs with even higher potencies and increase its capabilities to provide fully scalable HPAPI and ADC solutions from lab to commercialization, supporting the accelerated timelines that many drug programs in this category require.
“Supply from the facility is critical, and by supporting one of our global partners in the oncology field, we are enabling the treatment of many cancer patients,” said Maurits Janssen, Strategic Business Development Small Molecules at Lonza. “Oncology continues to be the leading indication in biopharma and a key driver for highly potent ingredients such as antibody-drug conjugates. We continue to add capabilities and capacity to meet the development and manufacturing needs of our partners in this field to answer to their increasing demand.”

“This partnership is a great example of how we can support both early and commercial-stage biopharmaceutical companies through innovation in manufacturing technology and flexible business models,” added Gordon Bates, President Small Molecules at Lonza. “Our customers developing highly potent and increasingly complex medicines need a partner whom they can trust to handle these toxic substances throughout their lifecycle and to deliver in sync with their needs, whether for clinical or for commercial supply. Our partner has recognized the value in combining expertise in biologics and chemistry on one site and this investment has expanded our collaboration.”

For more information visit www.chemanager-online.com/en/

View more Industry News

Latest News